Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 507.99 Billion KRW | 12.0% |
| 2022 | 453.55 Billion KRW | 5.58% |
| 2021 | 429.57 Billion KRW | 28.15% |
| 2020 | 335.21 Billion KRW | 2.35% |
| 2019 | 327.53 Billion KRW | 18.91% |
| 2018 | 275.43 Billion KRW | 21.23% |
| 2017 | 227.2 Billion KRW | 5.83% |
| 2016 | 214.68 Billion KRW | 10.23% |
| 2015 | 194.74 Billion KRW | 7.82% |
| 2014 | 180.61 Billion KRW | 12.79% |
| 2013 | 160.13 Billion KRW | 8.85% |
| 2012 | 147.12 Billion KRW | 4.8% |
| 2011 | 140.38 Billion KRW | 8.91% |
| 2010 | 128.89 Billion KRW | 17.62% |
| 2009 | 109.58 Billion KRW | 31.83% |
| 2008 | 83.12 Billion KRW | 11.1% |
| 2007 | 74.82 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 560.99 Billion KRW | 10.43% |
| 2024 Q2 | 582.84 Billion KRW | 3.89% |
| 2023 Q2 | 458.61 Billion KRW | 0.6% |
| 2023 Q4 | 507.99 Billion KRW | 6.15% |
| 2023 FY | 507.99 Billion KRW | 12.0% |
| 2023 Q1 | 455.88 Billion KRW | 0.52% |
| 2023 Q3 | 478.54 Billion KRW | 4.35% |
| 2022 Q1 | 449.07 Billion KRW | 4.54% |
| 2022 FY | 453.55 Billion KRW | 5.58% |
| 2022 Q4 | 453.55 Billion KRW | -2.12% |
| 2022 Q3 | 463.37 Billion KRW | 2.13% |
| 2022 Q2 | 453.68 Billion KRW | 1.03% |
| 2021 FY | 429.57 Billion KRW | 28.15% |
| 2021 Q2 | 391.15 Billion KRW | 13.14% |
| 2021 Q1 | 345.72 Billion KRW | 3.14% |
| 2021 Q3 | 418.57 Billion KRW | 7.01% |
| 2021 Q4 | 429.57 Billion KRW | 2.63% |
| 2020 FY | 335.21 Billion KRW | 2.35% |
| 2020 Q4 | 335.21 Billion KRW | 0.6% |
| 2020 Q2 | 324.05 Billion KRW | -1.53% |
| 2020 Q3 | 333.21 Billion KRW | 2.83% |
| 2020 Q1 | 329.08 Billion KRW | 0.47% |
| 2019 Q3 | 311.6 Billion KRW | 2.74% |
| 2019 Q2 | 303.29 Billion KRW | 3.04% |
| 2019 FY | 327.53 Billion KRW | 18.91% |
| 2019 Q4 | 327.53 Billion KRW | 5.11% |
| 2019 Q1 | 294.33 Billion KRW | 6.86% |
| 2018 Q4 | 275.43 Billion KRW | 9.22% |
| 2018 FY | 275.43 Billion KRW | 21.23% |
| 2018 Q1 | 240.8 Billion KRW | 5.98% |
| 2018 Q2 | 244.32 Billion KRW | 1.46% |
| 2018 Q3 | 252.19 Billion KRW | 3.22% |
| 2017 Q1 | 218.05 Billion KRW | 1.57% |
| 2017 Q4 | 227.2 Billion KRW | -1.33% |
| 2017 FY | 227.2 Billion KRW | 5.83% |
| 2017 Q2 | 221.42 Billion KRW | 1.54% |
| 2017 Q3 | 230.26 Billion KRW | 3.99% |
| 2016 Q2 | 203.43 Billion KRW | 2.25% |
| 2016 FY | 214.68 Billion KRW | 10.23% |
| 2016 Q1 | 198.95 Billion KRW | 2.16% |
| 2016 Q4 | 214.68 Billion KRW | 4.74% |
| 2016 Q3 | 204.96 Billion KRW | 0.75% |
| 2015 FY | 194.74 Billion KRW | 7.82% |
| 2015 Q3 | 185.51 Billion KRW | 1.36% |
| 2015 Q4 | 194.74 Billion KRW | 4.98% |
| 2015 Q2 | 183.03 Billion KRW | -1.54% |
| 2015 Q1 | 185.89 Billion KRW | 2.92% |
| 2014 Q1 | 166.02 Billion KRW | 3.67% |
| 2014 FY | 180.61 Billion KRW | 12.79% |
| 2014 Q4 | 180.61 Billion KRW | 4.7% |
| 2014 Q3 | 172.5 Billion KRW | 3.89% |
| 2014 Q2 | 166.05 Billion KRW | 0.02% |
| 2013 Q3 | 156.92 Billion KRW | 1.27% |
| 2013 Q2 | 154.96 Billion KRW | 4.14% |
| 2013 Q4 | 160.13 Billion KRW | 2.05% |
| 2013 FY | 160.13 Billion KRW | 8.85% |
| 2013 Q1 | 148.8 Billion KRW | 1.14% |
| 2012 Q1 | 142.17 Billion KRW | 0.0% |
| 2012 FY | 147.12 Billion KRW | 4.8% |
| 2012 Q4 | 147.12 Billion KRW | 0.0% |
| 2011 FY | 140.38 Billion KRW | 8.91% |
| 2011 Q2 | 134.43 Billion KRW | 0.14% |
| 2011 Q1 | 134.24 Billion KRW | 4.15% |
| 2011 Q3 | 136.61 Billion KRW | 1.62% |
| 2010 Q3 | 126.38 Billion KRW | 5.78% |
| 2010 Q1 | 113.94 Billion KRW | 3.98% |
| 2010 FY | 128.89 Billion KRW | 17.62% |
| 2010 Q4 | 128.89 Billion KRW | 1.99% |
| 2010 Q2 | 119.47 Billion KRW | 4.85% |
| 2009 Q3 | 90.57 Billion KRW | 2.6% |
| 2009 FY | 109.58 Billion KRW | 31.83% |
| 2009 Q4 | 109.58 Billion KRW | 20.99% |
| 2009 Q1 | 87.16 Billion KRW | 4.86% |
| 2009 Q2 | 88.27 Billion KRW | 1.27% |
| 2008 Q3 | 82.41 Billion KRW | 2.85% |
| 2008 Q1 | 78.05 Billion KRW | 4.32% |
| 2008 FY | 83.12 Billion KRW | 11.1% |
| 2008 Q2 | 80.13 Billion KRW | 2.66% |
| 2008 Q4 | 83.12 Billion KRW | 0.87% |
| 2007 Q1 | 67.41 Billion KRW | 0.0% |
| 2007 Q4 | 74.82 Billion KRW | -1.19% |
| 2007 FY | 74.82 Billion KRW | 0.0% |
| 2007 Q2 | 67.37 Billion KRW | -0.05% |
| 2007 Q3 | 75.72 Billion KRW | 12.38% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -156.288% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 74.043% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 42.075% |
| HANDOK Inc. | 790.33 Billion KRW | 35.724% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -197.737% |
| Yuhan Corporation | 2814.07 Billion KRW | 81.948% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 61.375% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -443.436% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 73.976% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -111.889% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -8.338% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -341.84% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -114.754% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -45.815% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -156.288% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -21.186% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -1.645% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 13.81% |
| JW Holdings Corporation | 1176.26 Billion KRW | 56.813% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 16.893% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 63.777% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 21.245% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -45.108% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -229.781% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -37.045% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -4.242% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -156.288% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 52.879% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 71.305% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 21.245% |
| Yuhan Corporation | 2814.07 Billion KRW | 81.948% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 42.273% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -124.182% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 48.88% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 21.245% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -20.98% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -8.347% |
| CKD Bio Corp. | 293.78 Billion KRW | -72.915% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 10.084% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -26.611% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -45.108% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 65.11% |
| Boryung Corporation | 922.36 Billion KRW | 44.924% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -14.812% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -8.338% |
| JW Lifescience Corporation | 255.83 Billion KRW | -98.564% |